Events

RSA Inspiring Leaders Webinar w/ Jackie Hunter

In this webinar, participants will hear from four distinguished industry leaders with inspiring stories.

They will share insights on the experiences, people and decisions that shaped their successful careers, talking about what constitutes great leadership and how that contributes to innovative, breakthrough science.

Speakers
  • Jo Pisani, Non-Executive Director, The RSA Group
  • Dr. Niven R Narain, Co-founder, President & CEO, BERG
  • Prof. Jackie Hunter, Board Director BenevolentAI
  • Shiva Dustdar, Head of Division, Innovation Finance Advisory for the European Investment Bank
Who Should Attend?

Senior professionals who are:

  • Aspiring and existing leaders from any sector or background
  • Life science executives searching for leadership advice
  • Women in leadership looking for guidance and role models
  • C-suite professionals
What You Will Learn

In this webinar, participants will gain:

  • Advice from the experts on what good, effective, inclusive leadership means
  • How to achieve this leadership and the mindset needed to lead well
  • Insights on building resilience, facing adversity, embracing your differences and being confident
  • An understanding of why diversity is vital to success
  • Advice that leaders from any industry sector would gain incredible value from
Register here →


Jackie Hunter

Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.

More Posts

You Might Also Like

News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021